Regular Article
DHEA and Its Transformation into Androgens and Estrogens in Peripheral Target Tissues: Intracrinology

https://doi.org/10.1006/frne.2001.0216Get rights and content

Abstract

A new understanding of the endocrinology of menopause is that women, at menopause, are not only lacking estrogens resulting from cessation of ovarian activity but have also been progressively deprived for a few years of androgens and some estrogens originating from adrenal DHEA and androstenedione (4-dione). In fact, serum DHEA decreases by about 60% between the maximal levels seen at 30 years of age to the age of menopause. This decreased secretion of DHEA and DHEA-S by the adrenals is responsible for a parallel decrease in androgen and estrogen formation in peripheral tissues by the steroidogenic enzymes specifically expressed in each cell type in individual target tissues. This new field of endocrinology, called intracrinology, describes the local synthesis of androgens and estrogens made locally in each cell of each peripheral tissue from the adrenal precursors DHEA and 4-dione. These androgens and estrogens exert their action in the same cells where their synthesis takes place and they are released from these target cells only after being inactivated. To further understand the effect of DHEA in women, DHEA has been administered in postmenopausal women for 12 months. Such treatment resulted in increased bone formation and higher bone mineral density accompanied by elevated levels of osteocalcin, a marker of bone formation. Vaginal maturation was stimulated, while no effect was observed on the endometrium. Preclinical studies, on the other hand, have shown that, due to its predominant conversion into androgens, DHEA prevents the development and inhibits the growth of dimethylbenz(a)anthracene-induced mammary carcinoma in the rat, a model of breast cancer. DHEA also inhibits the growth of human breast cancer ZR-75-1 xenografts in nude mice. The inhibitory effect of DHEA on breast cancer is due to an androgenic effect of testosterone and dihydrotestosterone made locally from DHEA. When used as replacement therapy, DHEA is free of the potential risk of breast and uterine cancer, while it stimulates bone formation and vaginal maturation and decreases insulin resistance. The combination of DHEA with a fourth generation SERM, such as EM-652 (SCH 57068), a compound having pure and potent antiestrogenic activity in the mammary gland and endometrium, could provide major benefits for women at menopause (inhibition of bone loss and serum cholesterol levels) with the associated major advantages of preventing breast and uterine cancer. A widely used application of intracrinology is the treatment of prostate cancer where the testicles are blocked by an LHRH agonist while the androgens made locally in the prostate from DHEA are blocked by a pure antiandrogen. Such treatment, called combined androgen blockade, has led to the first demonstration of a prolongation of life in prostate cancer.

References (106)

  • J Fomitcheva et al.

    Characterization of Ke 6, a new 17beta-hydroxysteroid dehydrogenase, and its expression in gonadal tissues

    J Biol Chem

    (1998)
  • D Ghosh et al.

    Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20A resolution

    Structure

    (1995)
  • GB Gordon et al.

    Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone

    Adv Enzyme Regul

    (1987)
  • EP Jenkins et al.

    Characterization and chromosomal mapping of human steroid 5α-reductase gene and pseudogene and mapping of the mouse homologue

    Genomics

    (1991)
  • CC Johnston et al.

    Clinical, biochemical, radiographic, epidemiologic, and economic features of osteoporosis

    Orthop Clin N Am

    (1981)
  • YY Kikuti et al.

    Physical mapping 220 kb centromeric of the human MHC and DNA sequence analysis of the 43-kb segment including the RING1, HKE6, and HKE4 genes

    Genomics

    (1997)
  • A Krazeisen et al.

    Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1)

    FEBS Lett

    (1999)
  • F. Labrie

    Intracrinology

    Mol Cell Endocrinol

    (1991)
  • F Labrie et al.

    Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival

    J Steroid Biochem

    (1985)
  • F Labrie et al.

    The key role of 17β-HSDs in sex steroid biology

    Steroids

    (1997)
  • F Labrie et al.

    Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues

    J Steroid Biochem Mol Biol

    (1992)
  • F Labrie et al.

    Structure and tissue-specific expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues

    J Steroid Biochem Mol Biol

    (1992)
  • F Labrie et al.

    Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues

  • Y Lachance et al.

    Characterization of human 3β-hydroxysteroid dehydrogenase/Δ54 isomerase gene and its expression in mammalian cells

    J Biol Chem

    (1990)
  • SX Lin et al.

    Subunit identity of the dimeric 17β-hydroxysteroid dehydrogenase from human placenta

    J Biol Chem

    (1992)
  • RA Lobo

    Absorption and metabolic effects of different types of estrogens and progestogens

    Obstet Gynecol Clin N Am

    (1987)
  • V Luu-The et al.

    Characterization, expression and immunohistochemical localization of 5α-reductase in human skin

    J Invest Dermatol

    (1994)
  • V Luu-The et al.

    Characteristics of human types 1, 2, and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation-reduction and inhibition

    J Steroid Biochem Mol Biol

    (1995)
  • EG MacEwen et al.

    Obesity in the dog: Role of the adrenal steroid dehydroepiandrosterone (DHEA)

    J Nutr

    (1991)
  • C Martel et al.

    Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase/Δ54 isomerase (3β-HSD), 17β-HSD 5α-reductase and aromatase activities in the rhesus monkey

    Mol Cell Endocrinol

    (1994)
  • CA Mashchak et al.

    Comparison of pharmacodynamic properties of various estrogen formulations

    Am J Obstet Gynecol

    (1982)
  • L Milewich et al.

    3β-Hydroxysteroid dehydrogenase activity in tissues of human fetus determined with 5α-androstane-3β,17β-diol and dehydroepiandrosterone as substrates

    J Steroid Biochem Mol Biol

    (1993)
  • G Pelletier et al.

    Ontogeny and subcellular localization of 3β-hydroxysteroid dehydrogenase (3β-HSD) in the human and rat adrenal, ovary and testis

    J Steroid Biochem Mol Biol

    (1992)
  • H Peltoketo et al.

    Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA

    FEBS Lett

    (1988)
  • PE Pochi et al.

    Sebaceous gland response in man to the administration of testosterone, Δ4-androstenedione and dehydroisoandrosterone

    J Invest Dermatol

    (1969)
  • J Simard et al.

    Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency

    J Steroid Biochem Mol Biol

    (1995)
  • T Suzuki et al.

    Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells

    Clin Immunol Immunopathol

    (1991)
  • A Tchernof et al.

    Reduced testosterone and adrenal C19 steroid levels in obese men

    Metabolism

    (1995)
  • J Adamski et al.

    Molecular cloning of a novel widely expressed human 80 kDa 17β-hydroxysteroid dehydrogenase IV

    Biochem J

    (1995)
  • S Andersson et al.

    Deletion of steroid 5α-reductase 2 gene in male pseudophermaphroditism

    Nature

    (1991)
  • S Andersson et al.

    Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases

    Proc Natl Acad Sci USA

    (1990)
  • N Aziz et al.

    Jacques B, Brenner BM. Downregulation of Ke 6, a novel gene encoded within the major histocompatibility complex, in murine polycystic kidney disease

    Mol Cell Biol

    (1993)
  • AH Baillie et al.

    The distribution of hydroxysteroid dehydrogenase in human sebaceous glands

    Br J Dermatol

    (1966)
  • A Bélanger et al.

    Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer

    J Clin Endocrinol Metab

    (1986)
  • A Bélanger et al.

    Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men

    J Clin Endocrinol Metab

    (1994)
  • CL Bennett et al.

    Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide

    Prostate Cancer Prostatic Dis

    (1999)
  • AU Buzdar et al.

    Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of post-menopausal patients with metastatic breast carcinoma: Results of 2 randomized double-blind controlled multiinstitutional trials

    Cancer

    (1996)
  • C Chen et al.

    Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears

    Endocrinology

    (1996)
  • DL Coleman et al.

    Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice

    Diabetes

    (1982)
  • S Couillard et al.

    Effect of dehydroepiandrosterone and the antiestrogen EM-800 on the growth of human ZR-75-1 breast cancer xenografts

    J Natl Cancer Inst

    (1998)
  • Cited by (0)

    Address correspondence and reprint requests to Fernand Labrie, Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), 2705 Laurier Boulevard, Quebec City, Quebec, G1V 4G2, Canada. Fax: (418) 654-2735. E-mail: [email protected].

    View full text